Re: ACAD review from Biopharma
ACAD has simply been moving with the sector. There should be a run up to the March 12 decision date. Neuren on the other hand has been on a steep Northern trajectory. The sector is trying to break out. We’ll either get a bounce down today or we may finally break through. XBI looks like the teeth on a saw blade since the end of September (bottom of teeth at about 77 and top of teeth at about 84). Whether XBI bounces back down this week or finally punches through resistance at 84, I’ve got to believe that ACAD will move Northward over the next 2 months.